[nyschp.dop] Re: GP2B3A inhibitors & Stress Test Agents

From: "Bartlett, James" <jbartlet@xxxxxxxxxxxxxx>
To: "nyschp.dop@xxxxxxxxxxxxx" <nyschp.dop@xxxxxxxxxxxxx>
Date: Mon, 20 Jun 2016 14:51:33 +0000

Responses below.

Jim Bartlett, PharmD, BCPS
Lead Pharmacist
Kenmore Mercy Hospital |2950 Elmwood Ave |Kenmore, NY 14217
Phone: 716-447-6786 | Fax: 716-447-6311

[Description: Description: cid:image001.png@01CD0E64.F6A55040]

From: nyschp.dop-bounce@xxxxxxxxxxxxx [mailto:nyschp.dop-bounce@xxxxxxxxxxxxx] ;
On Behalf Of Tibi-Scherl, Leila
Sent: Monday, June 20, 2016 10:48 AM
To: 'nyschp.dop@xxxxxxxxxxxxx'
Subject: [nyschp.dop] GP2B3A inhibitors & Stress Test Agents

Good morning, all,

A member hospital would like feedback on your practices with GP2B3A inhibitors
and Stress Test Agents. Please respond YES or NO to the following two short
questions:

Is your hospital using to Aggrastat as the primary glycoprotein 2b/3a inhibitor
(as compared to Integrilin)?
[Jim Bartlett] No
Is your hospital using Lexiscan as the primary nuclear stress test agent?
[Jim Bartlett] Yes
Your time is greatly appreciated. Thank you in advance for taking the time to
respond!

Sincerely,
Leila
--
Leila M. Tibi-Scherl, Pharm.D.
VP, Pharmacy Practice
GNYHA Services, Inc. | 555 W. 57th Street, Suite 1156 | New York, NY 10019
* 212.259.0775 |È646.483.3333 |7 212.541.9032 |*
tibi@xxxxxxxxx<mailto:tibi@xxxxxxxxx>
www.pharmacy.gnyhaservices.com<http://www.pharmacy.gnyhaservices.com/>

PQ Please consider the environment before printing this email.

CONFIDENTIALITY NOTICE: This message is confidential, intended only for the
named recipient(s) and may contain information that is privileged, or exempt
from disclosure under applicable law.
If you are not the intended recipient(s), you are notified that the
dissemination, distribution or copying of this message is strictly prohibited.
If you receive this message in error, or are not the named recipient(s), please
notify the sender by reply e-mail, delete this e-mail from your computer, and
destroy any copies in any form immediately.
Receipt by anyone other than the named recipient(s) is not a waiver of any
attorney-client, work product, or other applicable privilege.
This message and all contents may be reviewed by authorized parties of the
Catholic Health System other than those named in the message header.

References:
- [nyschp.dop] GP2B3A inhibitors & Stress Test Agents
  - From: Tibi-Scherl, Leila

[nyschp.dop] Re: GP2B3A inhibitors & Stress Test Agents

Other related posts: